Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127 million. Beam Therapeutics is listed on the Nasdaq Global Select Market under the symbol “Beam.”

Based in Cambridge, Massachusetts, Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam Therapeutics is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Yoojin Nairn-Kim, Edward Peck and Daniel Chao. Partner David R. Bauer and associate Hilary Smith provided intellectual property advice. Partner Po Sit provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post